Leadership Transformation at Mammogen with Denise DeMan
Mammogen, a pioneering company in predictive health focused on women's health diagnostics, has embarked on a significant leadership change. The company has announced the appointment of Denise "DeeDee" DeMan as the Chairwoman of its Board of Directors. This strategic move signals a vibrant phase of growth and innovation for the company.
DeDee DeMan: A Leader in Life Sciences
Denise DeMan is well-known for her remarkable track record in building strong boards and executive teams within the life sciences sector. As the Founder, Chair, and CEO of Bench International, she brings over fifty years of invaluable experience in placing key directors and executives in esteemed healthcare organizations worldwide. DeMan has played a vital role in shaping the leadership teams responsible for groundbreaking healthcare innovations.
Commitment to Inclusive Governance
Throughout her illustrious career, DeMan has emphasized inclusive governance and executive excellence. Her notable initiatives, including the recognizable Bank of Women, work to ensure diverse voices are present at every level within organizations. This dedication aligns seamlessly with Mammogen’s vision to have women’s perspectives at the forefront of its operations, reflecting a commitment to shaping a more equitable future in healthcare.
Mammogen’s Innovative Solutions
Mammogen stands out with its flagship product, genTRU™. This blood-based early detection test for breast cancer is designed to identify the disease in its earliest stages, ensuring higher treatment success rates. The genTRU™ assay boasts an impressive sensitivity of over 99% and an 89% specificity for Stage I disease. These results are supported by extensive clinical validation and peer-reviewed research.
Pioneering Breast Cancer Screening
As the company gears up for commercialization, the significance of its genTRU™ screening test cannot be overstated. Aimed at addressing a pressing need for effective screening methods, this diagnostic innovation targets over 25 million women in the U.S. who are at risk for breast cancer according to established guidelines.
Message of Confidence from Leadership
Denise DeMan expressed her enthusiasm for joining Mammogen’s leadership at this pivotal moment. She remarked on the company’s readiness to deliver transformative value in an evolving healthcare landscape. DeMan highlighted that Mammogen's integration of validated science and robust leadership makes it uniquely positioned for success as it embarks on the next chapter of its journey.
Strengthening Board Governance
In her new role, DeMan will take charge of Mammogen's board governance strategy, focusing on fortifying the company's standing in the industry as it proceeds toward commercialization. Her wealth of experience and commitment to nurturing effective governance structures will play a critical role in guiding Mammogen through this exciting transition.
About Mammogen
Mammogen is at the forefront of revolutionizing women’s health diagnostics. With an unwavering commitment to early detection and quality-of-life preservation, the company aims to enhance accessibility and diagnostic capabilities through innovative science. Mammogen is proud to be women-built, women-led, and driven by purpose, focusing on delivering accurate solutions to pressing health challenges.
About Bench International
Bench International holds the distinction of being the longest-serving woman-founded executive search firm in the life sciences field. With over 50 years of expertise in advising boards and executive teams, Bench has a remarkable project completion rate and stands out for its commitment to driving innovation and success across the healthcare sector. The firm specializes in various leadership services, ensuring companies thrive in an ever-evolving market.
Frequently Asked Questions
1. Who is Denise "DeeDee" DeMan?
Denise "DeeDee" DeMan is the newly appointed Chairwoman of Mammogen's Board of Directors, bringing extensive experience from Bench International.
2. What is Mammogen's primary product?
Mammogen's flagship product is genTRU™, a blood-based assay for early detection of breast cancer, making a significant impact in women’s health diagnostics.
3. How does genTRU™ work?
The genTRU™ assay detects breast cancer at its earliest stages, demonstrating over 99% sensitivity and 89% specificity for Stage I disease.
4. What is the mission of Mammogen?
Mammogen aims to preserve quality of life through early, accessible health diagnostics powered by cutting-edge scientific advancements.
5. What role will DeMan play at Mammogen?
As Chairwoman, DeMan will guide the board governance strategy and support Mammogen's growth and commercialization efforts in the healthcare sector.
